68 Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients

Yasemin Sanli, Oner Sanli, Duygu Has Simsek, Rathan M. Subramaniam

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Treatment of high-risk prostate cancer (HRPCa) is challenging. Local staging and metastatic evaluation are important for the patient management. Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy. Current evidence suggests that these imaging modalities may also have a role for the management of patients with HRPCa. In this review, we discuss PSMA-based imaging modalities in the management of patients with HRPCa.

Original languageEnglish (US)
Pages (from-to)871-880
Number of pages10
JournalNuclear Medicine Communications
Volume39
Issue number10
DOIs
StatePublished - Oct 1 2018

Keywords

  • 68 Ga-PET/MRI
  • 68 Ga-PSMA PET/CT
  • high-risk prostate cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of '68 Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients'. Together they form a unique fingerprint.

  • Cite this